Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2013-10-16 Capital/Financing Update
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 11, 2013, reporting the entry into new material definitive agreements for an at-the-market equity program and the termination of a previous sales agreement. It details the terms of the new sales agreements and the termination of the prior agreement. The document includes exhibits such as the sales agreements and legal opinions but does not contain financial statements or detailed financial performance data. The primary content is about financing activities related to equity sales agreements. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (6788 characters) and content confirm it is a full report, not just an announcement or certification.
2013-10-16 English
S-3ASR Filing
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Ligand Pharmaceuticals Incorporated. It is a registration statement under the Securities Act of 1933, used for registering securities to be offered to the public. The text includes a prospectus describing the securities to be offered, risk factors, and other legal and financial information related to the offering. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2013-10-02 English
4 Filing
Director's Dealing
2013-09-25 English
SC 13D/A Filing
Major Shareholding Notification
2013-09-16 English
4 Filing
Director's Dealing
2013-09-13 English
4 Filing
Director's Dealing
2013-09-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.